CURE Pharmaceutical’s acquisition of Dyrdek Machine Portfolio company Chemistry Holdings by has officially closed!
Now with Chemistry Holdings’ technology, CURE’s platform can pursue multiple encapsulations methods for improving the solubility of active ingredients, such as Chemistry Holdings’ novel chewable delivery system, nanoemulsions, microemulsions, microcapsules and taste masking solutions.
CEO of CURE Pharmaceutical Rob Davidson says: “This acquisition brings capital as well as novel intellectual property and scientific expertise to CURE’s capabilities, helping us deliver on our promise to transform patient’s lives with breakthrough medical treatments.”
More info on the acquisition can be found here.
